the "twincretin"
2013 (key discovery paper by Finan/DiMarchi/Tschöp labs); program built through mid-2010s; FDA approved 2022
For nearly three decades, GIP was diabetes research's discarded hormone — some labs were even trying to block it, not boost it — until an Indiana University peptide chemist bet that fusing it into one molecule with GLP-1 would outperform either alone.
Tirzepatide's origin story starts with a hormone the field had all but buried. GIP (glucose-dependent insulinotropic polypeptide) was identified in 1971 as one of the gut's two "incretin" hormones — chemical messengers that tell the pancreas to release insulin after a meal — the other being the now-famous GLP-1. But when researchers gave GIP to people with type 2 diabetes, it flopped: in the diabetic state its signalling looked blunted and unreliable. Some researchers were so unimpressed they went the other way entirely, testing GIP blockers on the reasoning that switching the hormone off might help more than switching it on — while GLP-1 quietly hoovered up almost all the industry's money and produced blockbusters like exenatide, liraglutide, and semaglutide.
GIP's comeback was an outsider's bet. Richard DiMarchi — a peptide chemist who'd spent decades at Eli Lilly, where he did the chemistry behind the first genetically engineered human insulin, before decamping to Indiana University — teamed up with metabolism researcher Matthias Tschöp. Their idea, which DiMarchi called "unimolecular polypharmacy," was almost stubbornly simple: instead of prescribing two drugs, build a single peptide that physically welds both hormones' activity together, so a cell can never catch one signal without the other. A landmark 2013 paper (Finan et al.) delivered exactly that — a balanced GIP/GLP-1 co-agonist nicknamed a "twincretin" that beat either single-hormone drug in preclinical and early human studies.
Lilly licensed and industrialized the approach into tirzepatide (originally coded LY3298176): a 39-amino-acid peptide built on the native GIP backbone, chemically tweaked so it also grips the GLP-1 receptor, and finished with a fatty-diacid tail — the same albumin-hugging trick used in long-acting insulins — that stretches its effect out to a single weekly shot. Here's the detail worth savouring: tirzepatide isn't a GLP-1 drug with a bit of GIP bolted on. It's the reverse — a re-engineered GIP molecule, built on the backbone of the very hormone the field had spent thirty years trying to write off.
And it worked almost embarrassingly well. In the SURMOUNT-1 obesity trial, people on the top 15 mg dose lost an average of 22.5% of their body weight over 72 weeks — more than a fifth of the person — outpacing the single-agonist GLP-1 drugs and stunning a field that had assumed GIP was dead weight in the formula. Mounjaro (for type 2 diabetes) was FDA-approved on May 13, 2022, the first dual-incretin drug ever cleared; Zepbound, the identical molecule sold for obesity, followed in November 2023.
The backbone of this story is solid: GIP really was the incretin the field sidelined for decades, the 2013 \"twincretin\" paper is real, and the drug's structure is described accurately. We rated it \"embellished\" only because a few flourishes needed trimming — the original draft had the approval date a day off and framed a 2025 cardiovascular trial as proof tirzepatide is the \"most effective\" drug, when the trial actually showed it was merely non-inferior (not superior) to an older GLP-1 — both now corrected.
Tirzepatide sells as <b>Mounjaro</b> (type 2 diabetes) and <b>Zepbound</b> (chronic weight management), both once-weekly subcutaneous injections from Eli Lilly, and it's now one of the best-selling drugs on Earth — part of a boom in which roughly 1 in 8 U.S. adults say they've tried a GLP-1-class drug. An FDA shortage designation that had let compounding pharmacies sell cheaper off-brand copies was lifted in October 2024, after which the FDA moved to restrict compounded versions and push patients back to the branded product (list price around $1,000+/month versus $250–350 for compounded — a real access-and-equity flashpoint). A 2025 head-to-head cardiovascular outcomes trial, <b>SURPASS-CVOT</b>, found tirzepatide non-inferior to an older GLP-1 drug on major cardiac events, with favorable secondary metabolic and weight results, though it did not reach statistical superiority on the heart endpoint — and newer triple agonists (GIP/GLP-1/glucagon, like retatrutide) are already in Phase 3, aiming to dethrone it.
